• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    106.75 +0.30 (+0.28%)
    Streaming Delayed Price Updated: 1:40 PM EST, Jan 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    26 27 Next >
    News headline image
    Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
    From Merck & Co., Inc.
    Via Business Wire
    Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
    Via Investor Brand Network
    Topics Government
    News headline image
    Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
    From Merck Sharp & Dohme
    Via Business Wire
    News headline image
    Merck to Participate in the Citi 2025 Global Healthcare Conference
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
    From Merck Sharp & Dohme
    Via Business Wire
    Biotech Valuations Rise as New Clinical Platforms Show Progress
    Via Investor Brand Network
    News headline image
    Biotech Valuations Rise as New Clinical Platforms Show Progress
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces First-Quarter 2026 Dividend
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Participate in the Jefferies Global Healthcare Conference in London
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
    From Merck Sharp & Dohme
    Via Business Wire
    News headline image
    Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
    From Merck & Co., Inc.
    Via Business Wire
    Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
    Via Investor Brand Network
    News headline image
    Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
    EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
    From Merck & Co., Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    26 27 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.